SCHEMBL6086624

SCHEMBL6086624

COC(=O)C(O)CNc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 3/20 0.45
RAB9A P51151 2/20 0.45
LMNA P02545 2/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
AGTR1 P30556 1/20 0.44
TSHR P16473 1/20 0.42
GAA P10253 1/20 0.41
KDM4E B2RXH2 2/20 0.41
DNM1 Q05193 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6882197 0.86 MAPT (0.52) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL6024619 0.86 MAPT (0.52) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL4896553 0.86 MAPT (0.52) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL10163173 0.84 MAPT (0.54) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL27803980 0.81 KMT2A (0.50) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL412018 0.81 MAPT (0.50) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL239274 0.81 MAPT (0.50) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL555036 0.81 MAPT (0.50) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL5406733 0.81 MAPT (0.51) MAPTSMN1; SMN2HTTKMT2AALDH1A1
SCHEMBL5406742 0.81 MAPT (0.51) MAPTSMN1; SMN2HTTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117903033-A Synthesis method of taxane side chain intermediate 上海卓鼎生物技术有限公司 2024-04-19 CN disclosed
CN-104356157-B A kind of preparation method of chiral four-membered ring taxane side chain compound 江苏红豆杉药业有限公司 2017-08-18 CN disclosed
CN-106632297-A Docetaxel side chain 2'-derived novel taxanes antitumor compound as well as synthesis method and application thereof 吉林医药学院 2017-05-10 CN disclosed
CN-106632296-A Novel taxane anti-tumor compound as well as synthesis method and application thereof 吉林医药学院 2017-05-10 CN disclosed
CN-102010383-B Method for preparing docetaxel chiral side chain intermediate SHANGHAI BIOSUNDRUG SCIENCE & TECHNOLOGY CO LTD 2012-08-15 CN disclosed
CN-102010383-A Method for preparing docetaxel chiral side chain intermediate SHANGHAI BLOSUNDRUG SCIENCE & TECHNOLOGY CO LTD 2011-04-13 CN disclosed
CN-1310897-C A semi-synthetic process for the preparation of N debenzoylpaclitaxel INDENA SPA (IT) 2007-04-18 CN disclosed
US-7053222-B2 Semi-synthetic process for the preparation of N-debenzoylpaclitaxel INDENA S.P.A. (IT) 2006-05-30 US disclosed
EP-1495011-B1 A SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF N DEBENZOYLPACLITAXEL INDENA SPA (IT) 2005-12-28 EP disclosed
CN-1646512-A A semi-synthetic process for the preparation of N debenzoylpaclitaxel INDENA SPA (IT) 2005-07-27 CN disclosed
US-20050049297-A1 Semi-synthetic process for the preparation of N-debenzoylpaclitaxel INDENA S. P. A. (IT) 2005-03-03 US disclosed
EP-1495011-A1 A SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF N DEBENZOYLPACLITAXEL INDENA S.p.A. (IT) 2005-01-12 EP disclosed
US-20040005562-A9 Comprises tranferase protein associated with biosynthesis of taxoids for treating breast and ovarian cancers WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2004-01-08 US disclosed
WO-2003087077-A1 A SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF N­ DEBENZOYLPACLITAXEL INDENA S.P.A. (IT) 2003-10-23 WO disclosed
US-20030108891-A1 Transacylases of the paclitaxel biosynthetic pathway WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2003-06-12 US disclosed
CN-1216039-A Process for preparing taxol UPJOHN CO (US) 1999-05-05 CN disclosed
EP-0674630-A1 7-HALO- AND 7$g(b),8$g(b)-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PHARMACIA & UPJOHN COMPANY (US) 1995-10-04 EP disclosed
WO-1994013655-A1 7-HALO- AND 7β,8β-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM THE UPJOHN COMPANY (US) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049297-A1 Semi-synthetic process for the preparation of N-debenzoylpaclitaxel UGT2B7, UGT2B17, CYP3A7 MAPT 1892/4885SMN1; SMN2 1596/4885HTT 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.